Middle-East respiratory syndrome coronavirus vaccine - Organic Vaccines

Drug Profile

Middle-East respiratory syndrome coronavirus vaccine - Organic Vaccines

Alternative Names: MERS-CoV vaccine - Organic Vaccines

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator National Institutes of Health (USA); Organic Vaccines
  • Developer Organic Vaccines
  • Class Monoclonal antibodies; Vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Middle East respiratory syndrome coronavirus

Most Recent Events

  • 10 Apr 2017 Preclinical development completed in France before April 2014 (Parenteral)
  • 10 Apr 2017 Organic Vaccine's Middle-East respiratory syndrome coronavirus vaccine is available on Compassionate use basis for the treatment/prevention of Middle East respiratory syndrome coronavirus in Saudi Arabia (Parenteral) before April 2017 (Organic Vaccines pipeline, April 2017)
  • 01 Jul 2014 Preclinical trials in Middle East respiratory syndrome coronavirus in France (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top